Abstract
CPT-11 was given to 14 patients with CDDP-resistant recurrent ovarian carcinoma and 6patients with radiotherapy-resistant uterine cervical carcinoma between August 1994 and April 1996. At first, CPT-11 was given to 4 ovarian carcinomas in the defined method A of 100 mg/m2/ week. However, the side effects of diarrhea and leukocytopenia were too severe to maintain the therapy. In an effort to reduce these side effects, a new administration method was devised: an initial dose of 70mg/m2 followed by increasing the dose to 100 mg/m2 every 10 days. Administrating the medication nine times in this method was defined as one course of therapy. This new method of administrating CPT-11 was practiced in the following 16 cases. It proved to be apparently helpful in reducing the previous side effects of diarrhea and leukocytopenia. Since both grade3 diarrhea and grade3 leukocytopenia were particularly reduced, we could smoothly treat every patient according to our schedule. In view of the anti-cancer effect, response was observed in 2 of 10 ovarian carcinomas, and 3 of 6 uterine cervical carcinomas inculuding 1adenocarcinoma. We could suggest that our new method of CPT-11 administration is clinically useful. [Adv Obstet Gynecol 49 (2); 110 115, 1997 (H9.3)]
